Association between mobilization regimen and PFS after auto-SCT for multiple myeloma

摘要

Filgrastim (G-CSF) is commonly combined with either chemotherapy (typically CY) or plerixafor for mobilization of hematopoietic stem cells (HSCs) before auto-SCT for multiple myeloma. These G-CSF-based combinations are often preferred to G-CSF alone because they reliably allow collection of sufficient HSCs for multiple auto-SCTs. Few studies have examined the association between mobilization regimen and post-auto-SCT multiple myeloma outcomes. One retrospective analysis compared outcomes after mobilization with G-CSF+CY vs G-CSF alone and found no PFS difference; this study, however, pre-dated the availability of plerixafor and widespread use of pretransplant lenalidomide and bortezomib. The prospective, randomized study of plerixafor in multiple myeloma patients did not include a chemotherapy-based mobilization arm and did not report long-term multiple myeloma outcomes.